A retrospective study of Avibactam/ceftazidime in the treatment of Carbapenem-Resistant Enterobacteriaceae infections
Latest Information Update: 28 Sep 2016
Price :
$35 *
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Enterobacteriaceae infections; Gram-negative infections
- Focus Therapeutic Use
- 28 Sep 2016 New trial record